Takeda delivers beyond expectations
Japenese Takeda Pharmaceutical, which is partnered with Danish Lundbeck, saw revenue growth but a decline in profits in the first quarter of 2023/24, although the results were generally better than market expectations.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck board denies debated bonus scheme for incoming CEO
For subscribers